Search results
Showing 46 to 60 of 476 results for %s
This indicator covers the proportion of babies with a screen positive newborn hip result who attend for ultrasound scan of the hips within the designated timescale. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG96
Evidence summaries: new medicines – Integrated process statement (PMG11)
Evidence summaries: new medicines – Integrated process statement
Spinal cord stimulation for chronic pain of neuropathic or ischaemic origin (TA159)
Evidence-based recommendations on spinal cord stimulation for chronic pain of neuropathic or ischaemic origin in adults.
This quality standard covers identifying and managing atrial fibrillation (including paroxysmal, persistent and permanent atrial fibrillation, and atrial flutter) in adults (aged 18 and over). It describes high-quality care in priority areas for improvement.
View quality statements for QS93Show all sections
Sections for QS93
- Quality statements
- Quality statement 1: Anticoagulation to reduce stroke risk
- Quality statement 2: Use of aspirin
- Quality statement 3: Discussing options for anticoagulation
- Quality statement 4: Anticoagulation control
- Quality statement 5: Referral for specialised management
- Quality statement 6 (developmental): Self-monitoring of anticoagulation
- Update information
A quick guide for home care managers providing medicines support
This indicator covers the proportion of eligible people aged 60 to 74 years whose record shows a bowel screening test has been performed within the last 2.5 years. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG83
Evidence-based recommendations on naloxegol (Moventig) for treating opioid-induced constipation in adults.
Spesolimab for treating generalised pustular psoriasis flares [ID3963]
In development [GID-TA10871] Expected publication date: 18 June 2025
Methods for the development of NICE public health guidance (third edition) (PMG4)
Methods for the development of NICE public health guidance (third edition)
Summary of the evidence on co-enzyme Q10 for mitochondrial disorders in children to inform local NHS planning and decision-making
This is the user guide for submission of evidence to the National Institute for Health and Care Excellence (NICE) as part of the single technology appraisal and highly specialised technologies evaluations process. It explains what information NICE requires and the format in which it should be presented
implanted mesh. These specialist centres were commissioned by N H S England and N H S Improvement to begin operating in...
NICE's external assessment centre. 1.3 The NICE health technology appraisal(s) of lumacaftor/ivacaftor, tezacaftor/ivacaftor and...
Radiation dose monitoring software for medical imaging with ionising radiation (MIB127)
NICE has developed a medtech innovation briefing (MIB) on radiation dose monitoring software for medical imaging with ionising radiation .
Bair Hugger for measuring core temperature during perioperative care (MIB99)
NICE has developed a medtech innovation briefing (MIB) on Bair Hugger for measuring core temperature during perioperative care .